Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 18/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 18/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 16/20 | 1.00 |
| ▸ | CDK2 | P24941 | 16/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 16/20 | 1.00 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.86 |
| ▸ | MGMT | P16455 | 6/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8618498 | 0.87 | CDK1 (0.77) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL30176198 | 0.87 | CDK1 (0.77) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL15643444 | 0.87 | CDK1 (0.76) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL7807585 | 0.86 | CDK1 (0.76) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL6925968 | 0.85 | CDK1 (0.74) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL7985300 | 0.84 | CDK1 (1.00) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL10578850 | 0.81 | CDK1 (0.68) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| Methylguanine SCHEMBL231097 | 0.80 | CDK1 (0.69) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| Methylguanine SCHEMBL29903462 | 0.80 | CDK1 (0.69) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| 6-Chloroguanine SCHEMBL17187927 | 0.80 | DPP4 (0.69) | CDK1CCNB1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | claimed |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-02-12 | — | — | US | claimed |
| EP-3131914-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | Idenix Pharmaceuticals LLC (US) | 2017-02-22 | — | — | EP | claimed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | claimed |
| WO-2015161137-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | claimed |
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-02-12 | — | — | US | disclosed |
| EP-3131914-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | Idenix Pharmaceuticals LLC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| WO-2015161137-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
| EP-0417999-B1 | Antiviral compounds | WELLCOME FOUND (GB) | 1996-03-13 | — | — | EP | disclosed |
| EP-0671410-A1 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-09-13 | — | — | EP | disclosed |
| US-5185437-A | 6-substituted 2',3'-dideoxypurine nucleosides; treatment for human immunodeficiency virus and heptatis b virus | BURROUGHS WELLCOME CO. (US) | 1993-02-09 | — | — | US | disclosed |
| US-5153318-A | Viricides for hepatitis and human t-cell leukemia/lymphoma viruses | BURROUGHS WELLCOME CO. (US) | 1992-10-06 | — | — | US | disclosed |
| US-5068320-A | 2-amino-6-(cyclopropylamino)purine-9-β-D-2',3'-dideoxyribofuranoside and its pharmaceutically acceptable salts | BURROUGHS WELLCOME CO. (US) | 1991-11-26 | — | — | US | disclosed |
| CN-1051180-A | The nucleosides that is used for the treatment of | WELLCOME FOUND (GB) | 1991-05-08 | — | — | CN | disclosed |
| EP-0421819-A1 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-04-10 | — | — | EP | disclosed |
| EP-0421739-A1 | 3'-azido purine nucleoside | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-04-10 | — | — | EP | disclosed |
| EP-0417999-A1 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-03-20 | — | — | EP | disclosed |
| EP-0286425-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | CDK1 573/4885CCNB1 1096/4885CCNA2 361/4885 |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | RB1, NSUN2, METTL3 | CDK1 571/4885CCNB1 1131/4885CCNA2 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.